CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 Financial Highlights
- As of June 30, 2017, cash and cash equivalents totaled $29.8 million.
- Research and development expenses were $3.1 million for the second quarter of 2017, as compared to $2.9 million for the same period in 2016.
- General and administrative expenses were $2.4 million for the second quarter of 2017, as compared to $1.5 million for the same period in 2016.
